Cargando…

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022

The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Carla, Amata, Sara, Pibiri, Ivana, Pace, Andrea, Buscemi, Silvestre, Palumbo Piccionello, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178595/
https://www.ncbi.nlm.nih.gov/pubmed/37175436
http://dx.doi.org/10.3390/ijms24097728
_version_ 1785040902862929920
author Rizzo, Carla
Amata, Sara
Pibiri, Ivana
Pace, Andrea
Buscemi, Silvestre
Palumbo Piccionello, Antonio
author_facet Rizzo, Carla
Amata, Sara
Pibiri, Ivana
Pace, Andrea
Buscemi, Silvestre
Palumbo Piccionello, Antonio
author_sort Rizzo, Carla
collection PubMed
description The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted.
format Online
Article
Text
id pubmed-10178595
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101785952023-05-13 FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 Rizzo, Carla Amata, Sara Pibiri, Ivana Pace, Andrea Buscemi, Silvestre Palumbo Piccionello, Antonio Int J Mol Sci Review The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted. MDPI 2023-04-23 /pmc/articles/PMC10178595/ /pubmed/37175436 http://dx.doi.org/10.3390/ijms24097728 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rizzo, Carla
Amata, Sara
Pibiri, Ivana
Pace, Andrea
Buscemi, Silvestre
Palumbo Piccionello, Antonio
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
title FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
title_full FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
title_fullStr FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
title_full_unstemmed FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
title_short FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
title_sort fda-approved fluorinated heterocyclic drugs from 2016 to 2022
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178595/
https://www.ncbi.nlm.nih.gov/pubmed/37175436
http://dx.doi.org/10.3390/ijms24097728
work_keys_str_mv AT rizzocarla fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022
AT amatasara fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022
AT pibiriivana fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022
AT paceandrea fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022
AT buscemisilvestre fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022
AT palumbopiccionelloantonio fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022